Galcanezumab for the prevention of cluster headache

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Torelli P, Manzoni GC. Behavior during cluster headache. Curr Pain Headache Rep. 2005;9(2):113–119.
   PubMedGoogle Scholar
• Rozen TD, Fishman RS. Cluster headache in the united states of america: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache J Head Face Pain. 2012;52(1):99–113.
   PubMed Web of Science ®Google Scholar
• Bahra A, May A, Goadsby PJ. Cluster headache a prospective clinical study with diagnostic implications. Neurology. 2002;58(3):354–361.
   PubMed Web of Science ®Google Scholar
• Fischera M, Marziniak M, Gralow I, et al. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia. 2008;28(6):614–618.
   PubMed Web of Science ®Google Scholar
• Van Vliet JA, Eekers PJE, Haan J, et al. Features involved in the diagnostic delay of cluster headache. J Neurol Neurosurg Psychiatry. 2003;74(8):1123–1125.
   PubMed Web of Science ®Google Scholar
• Bjørn Russell M. Epidemiology and genetics of cluster headache. Lancet Neurol. 2004;3(5):279–283.
   PubMed Web of Science ®Google Scholar
• Torelli P, Beghi E, Manzoni GC. Cluster headache prevalence in the Italian general population. Neurology. 2005;64(3):469–474.
   PubMed Web of Science ®Google Scholar
• Pohl H, Gantenbein AR, Sandor PS, et al. Interictal burden of cluster headache: results of the EUROLIGHT cluster headache project, an internet-based, cross-sectional study of people with cluster headache. Headache. 2020;60(2):360–369.
   PubMed Web of Science ®Google Scholar
• Jensen RM, Lyngberg A, Jensen RH. Burden of cluster headache. Cephalalgia. 2007;27(6):535–541.
   PubMed Web of Science ®Google Scholar
• Brandt RB, Doesborg PGG, Haan J, et al. Pharmacotherapy for Cluster Headache. CNS Drugs. Adis. 2020;34(2):171–184.
   PubMed Web of Science ®Google Scholar
• D’amico D, Rigamonti A, Solari A, et al. Health-related quality of life in patients with cluster headache during active periods. Cephalalgia. 2002;22(10):818–821.
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012 May 18;13:31–70.
   PubMed Web of Science ®Google Scholar
• May A, Leone M, Áfra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13(10):1066–1077.
   PubMed Web of Science ®Google Scholar
• Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: the American headache society evidence-based guidelines. Headache. 2016;56(7):1093–1106.
   PubMed Web of Science ®Google Scholar
• Voiticovschi-Iosob C, Allena M, De Cillis I, et al. Diagnostic and therapeutic errors in cluster headache: a hospital-based study. J Headache Pain. 2014;15(1):56.
   PubMedGoogle Scholar
• Lademann V, Jansen JP, Evers S, et al. Evaluation of guideline-adherent treatment in cluster headache. Cephalalgia. 2016;36(8):760–764.
   PubMed Web of Science ®Google Scholar
• Huang WY, Lo MC, Wang SJ, et al. Topiramate in prevention of cluster headache in the Taiwanese. Neurol. India.. 2010;58(2):284–287.
   PubMed Web of Science ®Google Scholar
• MJA L, Pascual J, Pascual AM, et al. Topiramate in the prophylactic treatment of cluster headache. Headache. 2003;43(7):784–789.
   PubMed Web of Science ®Google Scholar
• Mauskop A. Vagus Nerve Stimulation Relieves Chronic Refractory Migraine and Cluster Headaches. Cephalalgia. 2005;25(2):82–86.
   PubMed Web of Science ®Google Scholar
• Gaul C, Diener H-C, Silver N, et al. Non-invasive vagus nerve stimulation for PREVention and acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia. 2016;36(6):534–546.
   PubMed Web of Science ®Google Scholar
• Schoenen J, Jensen RH, Lantéri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia. 2013;33(10):816–830.
   PubMed Web of Science ®Google Scholar
• Dodick D, Trentman T, Zimmerman R, et al. Occipital nerve stimulation for intractable chronic primary headache disorders. Cephalalgia. 2003;23:701.
   Web of Science ®Google Scholar
• Wilbrink LA, Teernstra OPM, Haan J, et al. Occipital nerve stimulation in medically intractable, chronic cluster headache. the ICON study: rationale and protocol of a randomised trial. Cephalalgia. 2013;33(15):1238–1247.
   PubMed Web of Science ®Google Scholar
• Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med. 2001;345(19):1428–1429.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European headache federation. J Headache Pain. 2013;14(1):86.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - Successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Emgality. cited 2020 Mar 5. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/emgality
   Google Scholar
• FDA. FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks. 06 April 2019. cited 2020 Mar 5. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks
   Google Scholar
• Eli Lilly and Company. EMGALITY [PRESCRIBING INFORMATION]. Indianapolis (IN): Eli Lilly and Company; 2019.
   Google Scholar
• A study to explore the long-term safety and efficacy of TEV-48125 (Fremanezumab) for the prevention of cluster headache (ENFORCE) . April 11, 2017. cited 2020 Mar 20. Available from: https://clinicaltrials.gov/ct2/show/NCT03107052.
   Google Scholar
• A study comparing the efficacy and safety of fremanezumab (TEV-48125) for the prevention of chronic cluster headache (CCH) . November. 16, 2016. cited 2020 Mar 20. Available from: https://clinicaltrials.gov/ct2/show/NCT02964338
   Google Scholar
• A study to evaluate the efficacy and safety of TEV-48125 (Fremanezumab) for the prevention of episodic cluster headache (ECH). Oct. 25, 2016. cited 2020 Mar 20. Available from: https://clinicaltrials.gov/ct2/show/NCT02945046
   Google Scholar
• Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides. 2001;22(6):995–1007.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997;120(1):193–209.
   PubMedGoogle Scholar
• Leone M, May A. Pathophysiological considerations regarding cluster headache and trigeminal autonomic cephalalgias. In: Leone M, May A, editors. Cluster headache and other trigeminal autonomic cephalalgias. Cham: Springer International Publishing; 2020. 57–66. [cited 2020 Jun 10]. Available from: http://link.springer.com/10.1007/978-3-030-12438-0_6
   Google Scholar
• Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298(5871):240–244.
   PubMed Web of Science ®Google Scholar
• Russell FA, King R, Smillie S-J, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4): 1099–1142.
   PubMed Web of Science ®Google Scholar
• Gibson SJ, Polak JM, Bloom SR, et al. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. J Neurosci. 1984;4(12):3101–3111.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CAA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–696.
   PubMed Web of Science ®Google Scholar
• Williamson D, Hargreaves R, Hill R, et al. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat—intravital microscope studies. Cephalalgia. 1997;17(4):525–531.
   PubMed Web of Science ®Google Scholar
• Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313(5997):54–56.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab—a humanized monoclonal anti-cgrp antibody—inhibits thinly myelinated (Aδ) but not unmyelinated (c) meningeal nociceptors. J Neurosci. 2017;37(44):10587–10596.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Warfvinge K, Krause DN, et al. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of ranvier in the trigeminal system. J Headache Pain. 2019;20(1):105.
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142(7):1171–1181.
   PubMed Web of Science ®Google Scholar
• Csati A, Tajti J, Tuka B, et al. Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion - Interaction with the sensory system. Brain Res. 2012;1435:29–39.
   PubMed Web of Science ®Google Scholar
• Hay DL, Garelja ML, Poyner DR, et al. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175(1): 3–17.
   PubMed Web of Science ®Google Scholar
• Bailey R, Walker C, Ferner A, et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol. 2012;166(1):151–167.
   PubMed Web of Science ®Google Scholar
• Hay DL, Christopoulos G, Christopoulos A, et al. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol. 2005;67(5):1655–1665.
   PubMed Web of Science ®Google Scholar
• Bailey RJ, Hay DL. Pharmacology of the human CGRP1 receptor in Cos 7 cells. Peptides. 2006;27(6):1367–1375.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(Pt 3):427–434.
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Alessandri M, Sicuteri R, et al. Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. Brain. 1997;120(2):283–288.
   PubMedGoogle Scholar
• Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60(2):119–123.
   PubMed Web of Science ®Google Scholar
• Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75(10):1187–1197.
   PubMed Web of Science ®Google Scholar
• Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr Cartil. 2014;22(4): 578–585.
   PubMed Web of Science ®Google Scholar
• Vermeersch S, Benschop RJ, Van Hecken A, et al. Translational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model. J Pharmacol Exp Ther. 2015;354(3):350–357.
   PubMed Web of Science ®Google Scholar
• Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:1–11.
   PubMed Web of Science ®Google Scholar
• Johnson KW, Morin SM, Wroblewski VJ, et al. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia. 2019;39(10):1241–1248.
   PubMed Web of Science ®Google Scholar
• Felgenhauer K, Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr. 1974;52(24):1158–1164.
   PubMedGoogle Scholar
• Dodick DW, Goadsby PJ, Spierings ELH, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885–892.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention a randomized clinical trial. JAMA Neurol. 2018;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2): 132–141.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;033310242090532. published online 12 February 2020. DOI:10.1177/0333102420905321.
   Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):E2211–E2221.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s). 2019. last accessed 2020 Mar 30. Available at: https://www.ema.europa.eu/en/documents/scientific-conclusion/emgality-h-c-psusa-00010733-201903-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf
   Google Scholar
• Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;1(1):25.
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188.
   PubMed Web of Science ®Google Scholar
• Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20(1):27.
   PubMed Web of Science ®Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain. 2017;18(1):1–9.
   PubMedGoogle Scholar
• Yallampalli C, Chauhan M, Endsley J, et al. Calcitonin gene related family peptides: importance in normal placental and fetal development. Adv Exp Med Biol. 2014;814:229–240.
   PubMed Web of Science ®Google Scholar
• [Committee for Medicinal Products for Human Use (CHMP). Emgality-H-C-04648-X-0004: EPAR - refusal public assessment report. Amsterdam; 2020. last accessed 2020 Jun 15. Available at: https://www.ema.europa.eu/en/documents/assessment-report/emgality-h-c-04648-x-0004-epar-refusal-public-assessment-report_en.pdf
   Google Scholar
• Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959–969.
   PubMed Web of Science ®Google Scholar
• Pearson SM, Burish MJ, Shapiro RE, et al. Effectiveness of Oxygen and other acute treatments for cluster headache: results from the cluster headache questionnaire, an international survey. Headache. 2019;59(2):235–249.
   PubMed Web of Science ®Google Scholar
• Snoer A, Vollesen ALH, Beske RP, et al. Calcitonin gene-related peptide and disease activity in cluster headache. Cephalalgia. 2019;39(5):575–584.
   PubMed Web of Science ®Google Scholar
• B, Szabó N, Tóth E, et al. Release of PACAP-38 in episodic cluster headache patients - An exploratory study. J Headache Pain. 2016;1(1):69.
   Google Scholar
• Ferraro S, Nigri A, Bruzzone MG, et al. Defective functional connectivity between posterior hypothalamus and regions of the diencephalic-mesencephalic junction in chronic cluster headache. Cephalalgia. 2018;38(13):1910–1918.
   PubMed Web of Science ®Google Scholar